The European Medicines Agency
has recommended marketing
approval for Daklinza (daclatasvir) in
combination with other medicines
for the treatment of chronic
hepatitis C virus infection in adults.
Daklinza is the first in a new class
of antivirals which block the action
of a protein which is used by the
hepatitis C virus to replicate.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Jul 14
PEAK industry bodies have welcomed Labor Government’s 2024-25 Commonwealth Budget handed down last night, which introduced financial relief measures aimed at assisting patients and community pharmacies.
AFFORDABLE healthcare for more Australians was highlighted in yesterday’s Federal Budget, with funds allocated to services for Aboriginal and Torres Strait Islander people.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.